Despite consistent observations that CP needed to be administered early in relation to the onset of the infection for optimal benefit (22–24); several studies were conducted, highlighting, not unexpectedly, that CP was ineffective in unselected patients with advanced disease, such as influenza (25). The gene discussed is CP; the disease is infection.